TMEM223: A Potential Drug Target and Biomarker for Chronic Pain Management

Target Name: TMEM223

NCBI ID: G79064

TMEM223

Other Name(s): transmembrane protein 223 | Mrx15 | TM223_HUMAN | Transmembrane protein 223

TMEM223: A Potential Drug Target and Biomarker for Chronic Pain Management

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that approximately 50% of the global population experiences chronic pain, with costs associated with pain reaching as much as $60 billion annually. Chronic pain can be caused by various conditions, such as neuropathic pain, inflammatory pain, and chronic non-cancer pain. While conventional pain management approaches, such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), can provide relief, these treatments often have adverse side effects. As such, there is an ongoing need for new, safer pain management options.

TMEM223: A Potential Drug Target and Biomarker

TMEM223 is a transmembrane protein located in the endoplasmic reticulum (ER) and characterized by its unique topology, where the cytoplasmic side of the protein is exposed to the ER lumen and the transmembrane region is covered by the endoplasmic reticulum. TMEM223 plays a crucial role in the regulation of intracellular signaling pathways, including the TGF-β pathway. TGF-β is a well-established mediator of pain modulation and has been implicated in the development and maintenance of chronic pain.

Recent studies have suggested that TMEM223 may be a potential drug target for chronic pain management. First, TMEM223 has been shown to be involved in the regulation of pain perception and neuroinflammation. Second, the function of TMEM223 has been investigated in the context of chronic pain modulation, including its potential as a biomarker for tracking the effectiveness of pain treatments.

TMEM223 as a Drug Target:

Several studies have demonstrated the potential of TMEM223 as a drug target for chronic pain management. First, TMEM223 has been shown to play a role in the regulation of pain perception by modulating the activity of TRPV1, an ion channel responsible for mediating pain signals. Activation of TRPV1 can lead to the sensation of pain, and blockade of TRPV1 has been shown to provide analgesia in experimental models of pain. Additionally, TMEM223 has been shown to interact with GPR91, a G protein-coupled receptor that plays a role in pain modulation. Activation of GPR91 can lead to the release of endogenous opioids and other neuromodulators, providing evidence for TMEM223's role in the regulation of pain.

TMEM223 as a Biomarker:

TMEM223 has also been investigated as a potential biomarker for tracking the effectiveness of pain treatments. The ability of TMEM223 to be targeted by small molecules and its unique subcellular localization have made it an attractive candidate for use as a drug monitor. Several studies have shown that TMEM223 can be modulated by small molecules, including those derived from natural compounds. For example, the neurotransmitter GABA has been shown to inhibit TMEM223 activity, while the opioid agonist U-57188 has been shown to increase its activity. These findings suggest that TMEM223 may be a sensitive biomarker for tracking the efficacy of pain treatments.

Conclusion

TMEM223 is a transmembrane protein that has been shown to play a crucial role in the regulation of pain modulation and may be a potential drug target for chronic pain management. Its unique subcellular localization and interaction with other molecules make it an attractive candidate for use as a biomarker for tracking the effectiveness of pain treatments. Further research is needed to fully understand the role of TMEM223 in pain modulation and its potential as a drug target.

Protein Name: Transmembrane Protein 223

Functions: Mitochondrial ribosome-associated protein involved in the first steps of cytochrome c oxidase complex (complex IV) biogenesis (PubMed:34969438). Stimulates the translation of MT-CO1 mRNA and is a constituent of early MT-CO1 assembly intermediates (PubMed:34969438)

The "TMEM223 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM223 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets